Table 2 Medication Use and Persistence by the 420 Patients Enrolled in the Stroke Outcome Study from 2001–2002 at the Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
Drug category | Users at discharge, n (%) | Users at 6 months, n (%) | Persistencea at 6 months (%) | Users at 12 months, n (%)b | Persistencec at 12 months (%)b |
|---|---|---|---|---|---|
Antihyperglycemic | 104 (24.8) | 104 (24.8) | 101/104 (97.1) | 103 (25.6) | 98/101 (97.0) |
   Insulin | 25 (6.0) | 26 (6.2) |  | 32 (8.0) |  |
   Oral agents | 87 (20.7) | 86 (20.5) |  | 82 (20.4) |  |
Antihypertensive | 384 (91.4) | 374 (89.0) | 363/384 (94.5) | 355 (88.3) | 348/367 (94.8) |
   Diuretic | 137 (32.6) | 140 (33.3) |  | 151 (37.6) |  |
   β-Blocker | 182 (43.3) | 176 (41.9) |  | 166 (41.3) |  |
   CCB | 96 (22.9) | 102 (24.3) |  | 96 (23.9) |  |
   ACE-I | 317 (75.5) | 291 (69.3) |  | 272 (67.7) |  |
   ARB | 21 (5.0) | 34 (8.1) |  | 40 (10.0) |  |
   Other | 7 (1.7) | 9 (2.1) |  | 10 (2.5) |  |
Antithrombotic | 405 (96.4) | 392 (93.3) | 385/405 (95.1) | 379 (94.3) | 372/387 (96.1) |
   Antiplateletd | 341 (81.7) | 333 (79.3) | 322/341 (94.4) | 322 (80.1) | 310/325 (95.4) |
   Anticoagulantd | 72 (17.1) | 71 (16.9) | 60/72 (83.3) | 69 (17.2) | 57/69 (82.6) |
Antilipidemic | 307 (73.1) | 304 (72.4) | 285/307 (92.8) | 300 (74.6) | 276/302 (91.4) |
   Statin | 306 (72.9) | 295 (70.2) |  | 293 (72.9) |  |
   Other | 1 (0.2) | 10 (2.4) |  | 9 (2.2) |  |
Combination use | Â | Â | Â | Â | Â |
   Antihypertensive and antithrombotic | 373 (88.8) | 360 (85.7) |  | 342 (85.1) |  |
   Antihypertensive, antithrombotic and antilipidemic | 286 (68.1) | 284 (67.6) |  | 274 (68.2) |  |